Pradžia › Ūmi limfoblastinė leukemija › Washington › Seattle
Ūmi limfoblastinė leukemija klinikiniai tyrimai Seattle, WA
Vienas tyrimas dėl Ūmi limfoblastinė leukemija ieško dalyvių vietoje Seattle arba jos apylinkėse. Atidarykite jį, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Renkami dalyviai
- Seattle Children's, University of Washington, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- ir dar 1
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Renkami dalyviai1 fazė
- Fred Hutchinson Cancer Center, Seattle
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Renkami dalyviai2 fazė
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Renkami dalyviai1/2 fazė
- Seattle Children's Hospital, Seattle
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Renkami dalyviaiStebimasis tyrimas
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Multicenter HomeVENT: Home Values and Experiences Navigation Track
Renkami dalyviaiLaukiami sveiki savanoriai
- Seattle Childrens Hospital, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Renkami dalyviaiStebimasis tyrimas
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Renkami dalyviai1/2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Renkami dalyviai1/2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Renkami dalyviai1 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Renkami dalyviaiStebimasis tyrimas
- Seattle Children's Hospital, Seattle
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Renkami dalyviai3 fazė
- Ascentage Investigative Site #1806, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Renkami dalyviai2 fazė
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Renkami dalyviai1 fazė
- Fred Hutchinson Cancer Research Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Renkami dalyviai1 fazė
- Fred Hutchinson Cancer Center, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Renkami dalyviai1 fazė
- Seattle Children's Hospital, Seattle
Ūmi limfoblastinė leukemija tyrimai kituose miestuose
- Houston, TX28 tyrimai
- New York City, NY24 tyrimai
- Baldwin Park, CA21 tyrimas
- Chicago, IL19 tyrimai
- Atlanta, GA19 tyrimai
- Philadelphia, PA16 tyrimai
- Memphis, TN16 tyrimai
- Washington, DC16 tyrimai
- Boston, MA15 tyrimai
- Los Angeles, CA14 tyrimai
- Durham, NC13 tyrimai
- Mountain View, CA13 tyrimai
Kiti tyrimai Seattle
- Nedidelinių ląstelių plaučių vėžys53 tyrimai
- Vėžys (visų tipų)49 tyrimai
- Prostatos vėžys42 tyrimai
- Ūmi mieloidinė leukemija40 tyrimai
- Krūties vėžys39 tyrimai
- Metastatinis vėžys39 tyrimai
- Storosios ir tiesiosios žarnos vėžys34 tyrimai
- Plaučių vėžys33 tyrimai
- Kiaušidžių vėžys30 tyrimai
- Kartotinė mieloma22 tyrimai
- Mielodisplastiniai sindromai21 tyrimas
- Šlapimo pūslės vėžys21 tyrimas
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.